ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ BỆNH VIÊM GAN VI RÚT B MẠN TÍNH BẰNG ENTERCAVIR Ở TRẺ EM DƯỚI 12 TUỔI TẠI BỆNH VIỆN BỆNH NHIỆT ĐỚI TRUNG ƯƠNG

Abstract

Objectives: To evaluate the clinical and subclinical effectiveness of entercavir treatment regimens in children under 12 years of age who were monitored at the Pediatric Outpatient Clinic, National Hospital for Tropical Diseases.

Subjects and Methods: A cross-sectional descriptive study with analysis of 48 children under 12 years of age with a diagnosis of chronic hepatitis B virus being treated with the antiretroviral drug entercavir at the Pediatrics Department, National Hospital for Tropical Diseases. January, 2017 -December, 2021.

Results and conclusions: Children with chronic hepatitis B virus infection have marked clinical improvement after 1 and 3 months of treatment. Normal enzyme AST after 3, 6, 9, 12 months was: 43.8%, 75%, 89.6% and 87.5%, the proportion of patients with normal ALT activity after 3, 6, 9, 12 months were: 33.3%, 64.6%, 85.4% and 85.4%. The rates of seroconversion after 6 months, 12 months were 10.9% and 21.7%. Patients with HBV DNA load below the detection threshold after 6, 12 months are: 27.1% and 45.8%, 02/48 patients with ideal score lost HBsAg and developed AntiHBs after 12 months of treatment with entercavir.